Cellebrite DI Ltd. (CLBT) Stock Price & Analysis
Cellebrite DI Ltd. (CLBT) closed at USD 11.38 on Thursday, October 15, 2026, up 5.08% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.83; the Oct 15, 2026 session ranged USD 10.68–11.42 on volume of 2,615,356 shares. Market capitalization is $2.86B, with a 52-week range of USD 9.58–19.98 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CLBT.md
Key facts (CLBT)
- Analysts: Buy (mean 1.75 on a 1–5 scale) (8 analysts), mean target USD 15.36 (range 12.5–20).
- Total return with dividends: 1Y -37.1% vs S&P 500 +18.1%; 5Y +9.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD 0.16, revenue estimate $146M.
Analysts (CLBT)
Consensus Buy (mean 1.75 on a 1–5 scale), 8 analysts; mean target USD 15.36 (low 12.5, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-15 | DA Davidson | Maintained | Buy | $15 |
| 2026-08-14 | Lake Street | Target lowered | Buy | $21 → $15 |
| 2026-08-14 | JP Morgan | Target lowered | Overweight | $20 → $16 |
| 2026-08-14 | DA Davidson | Target lowered | Buy | $22 → $15 |
| 2026-08-14 | Needham | Target lowered | Buy | $15 → $12.5 |
| 2026-08-06 | DA Davidson | Target raised | Buy | $20 → $22 |
Total return (dividends reinvested) (CLBT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -37.1% | +9.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -37.2% | +1.9% |
| Volatility (annualized) | 64.0% | 50.7% |
| Max drawdown | -45.9% (Nov 2025→Aug 2026) | -64.9% (Oct 2021→Sep 2022) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 11.38 |
|---|---|
| Change | ▲ 5.08% (up) |
| Previous Close | USD 10.83 |
| Open | USD 10.68 |
| Day Range | USD 10.68 – 11.42 |
| 52-Week Range | USD 9.58 – 19.98 |
| Volume | 2,615,356 shares |
| Market Cap | $2.86B |
| Exchange | NMS |
Technical Analysis (CLBT)
Nexqual's technical model rates CLBT "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.35 (neutral) |
| vs SMA50 | Below (USD 11.8) |
| MACD | -0.17 (negative) |
Analyst Ratings (CLBT)
Wall Street analysts rate CLBT "Buy" based on 8 analysts, with a mean price target of USD 15.36 (range USD 12.5–20), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 15.36 |
| High Target | USD 20 |
| Low Target | USD 12.5 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (CLBT)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD 0.16 |
| Revenue Estimate | $145.89M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.11 vs est 0.11 ▼ miss |
| 2026-03-31 | USD 0.12 vs est 0.1 ▲ beat |
| 2025-12-31 | USD 0.14 vs est 0.14 ▲ beat |
| 2025-09-30 | USD 0.14 vs est 0.13 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (CLBT)
| Total Revenue | $514.29M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +15.80% |
| Gross Margin | +82.96% |
| Operating Margin | +5.30% |
| Profit Margin | +11.43% |
| ROE | +12.42% |
| Debt / Equity | 0.04 |
| Current Ratio | 1.62 |
| Total Cash | $442.53M |
| Total Debt | $23.23M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (CLBT)
Nexqual rates Cellebrite DI Ltd.'s overall financial health "Solid" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +19% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 83%, operating 5% |
| Balance Sheet | Strong — $443M cash vs $23M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $158M (TTM) |
| Efficiency | Mixed — ROE 12%, ROA 3.9% |
Ownership (CLBT)
| Insider Ownership | +43.54% |
|---|---|
| Institutional Ownership | +53.26% |
| Shares Outstanding | 251.34M |
| Float | 99.27M |
| Short % of Float | +5.71% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (CLBT)
Cellebrite DI Ltd. is led by Shiven Ramji, CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO & Director | Shiven Ramji |
|---|---|
| Chief Financial Officer | David Barter (age 53) |
| Global Chief Revenue Officer | Marcus Jewell (age 52) |
| Chief Technology Officer | Christopher Wade (age 41) |
| Chief Marketing Officer | David Nicholas Gee (age 58) |
Major Backers & Investors (CLBT)
Notable institutional backers of Cellebrite DI Ltd. include True Wind Capital Management, L.P., Voss Capital, LP, Pertento Partners LLP, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| True Wind Capital Management, L.P. | 5.56% |
| Voss Capital, LP | 4.59% |
| Pertento Partners LLP | 3.21% |
| Fidelity | 2.65% |
| Phoenix Financial Ltd. | 2.48% |
| FMR, LLC | 2.39% |
| Nine Ten Capital Management LLC | 1.65% |
| SmallCap World Fund Inc | 1.63% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.65% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PAY | Paymentus Holdings, Inc. | USD 32.13 | ▲ 0.82% |
| TENB | Tenable Holdings, Inc. | USD 39.32 | ▼ 4.77% |
| DLO | DLocal Limited | USD 15.1 | ▲ 0.53% |
| CORZ | Core Scientific, Inc. | USD 14.46 | ▼ 6.32% |
| BLSH | Bullish | USD 31.87 | ▲ 0.31% |
| BB | BlackBerry Limited | USD 8.7 | ▲ 2.72% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt